TP53 and cancer: Besides, we and others have shown that in cancer cells retaining wild-type p53, the inhibition of RNA polymerase II-mediated transcription by small-molecule CDKIs can lead to non-genotoxic activation of p53-dependent transcription, potentially contributing to their cytotoxic activity12–16.